

DMD #39180

Combination of glutathione trapping and time-dependent inhibition assays as a predictive method drugs generating highly reactive metabolites

Shintaro Nakayama^{*}, Hideo Takakusa, Akiko Watanabe, Yoshihiro Miyaji, Wataru Suzuki, Daisuke Sugiyama, Kazuhito Shiosakai, Kokichi Honda, Noriko Okudaira, Takashi Izumi, and Osamu Okazaki

Drug Metabolism and Pharmacokinetics Research Laboratories (S.N., H.T., A.W., Y.M., W.S., D.S., T.I.), Daiichi Sankyo Co., Ltd., 1-2-58, Hiromachi, Shinagawa-ku, Tokyo, 140-8710, Japan

Clinical Data and Biostatistics Department (K.S., K.H.), Daiichi Sankyo Co., Ltd., 1-2-58, Hiromachi, Shinagawa-ku, Tokyo, 140-8710, Japan

R&D Planning Department (O.O.), Daiichi Sankyo Co., Ltd., 1-2-58, Hiromachi, Shinagawa-ku, Tokyo, 140-8710, Japan

DMD #39180

Running title: Minimizing metabolic activation by GSH trapping and TDI assay

Address correspondence to: Shintaro Nakayama

Drug Metabolism and Pharmacokinetics Research Laboratories, R&D Division, Daiichi

Sankyo Co., Ltd.

1-2-58, Hiromachi, Shinagawa-ku,

Tokyo, 140-8710, Japan

Tel: (81) 3-3492-3131

Fax: (81) 3-5436-8567

E-mail: nakayama.shintaro.gg@daiichisankyo.co.jp

Number of text pages: 28 (including references and legends)

Number of tables: 3

Number of figures: 3

Number of references: 56

Number of words:

Abstract: 244

Introduction: 549

Discussion: 1122

Nonstandard abbreviations:

CB, covalent binding; IDT, idiosyncratic drug toxicity; G6P, glucose-6-phosphate;

G6PDH, glucose-6-phosphate dehydrogenase; GSH, glutathione; HLM, human liver

microsome; RM, reactive metabolite; TDI, time-dependent inhibition; MBI,

mechanism-based inhibition; $CL_{int, RMs}$, combined intrinsic clearance for forming RMs;

LC/MS; liquid chromatography mass spectrometry

DMD #39180

Abstract

Covalent binding (CB) of reactive metabolites (RMs) is potentially involved in severe adverse drug reactions. Because the CB assay is of low throughput and costly, a qualitative trapping assay using agents such as [³⁵S]glutathione (GSH) is often performed in the early stages of drug discovery. Trapping methods alone, however, cannot replace the CB assay. We hypothesized that the time-dependent inhibition (TDI) assay might be complementary to [³⁵S]GSH trapping assay in detecting RMs. We performed CB assays, [³⁵S]GSH trapping assays, and TDI assays for 42 structurally diverse compounds. First, we showed that the [³⁵S]GSH trapping assay alone does not correlate with the extent of CB. Four compounds that [³⁵S]GSH trapping assay failed to detect but showed high extent of CB were inactivators of the enzyme in the TDI assay. There was a tendency for compounds judged as positive in the TDI assay to show a high degree of the extent of CB irrespective of the result of the [³⁵S]GSH trapping assay. Finally, to combine parameters from the two assays, we introduced intrinsic clearance to describe the formation of RMs ($CL_{int, RMs}$). The Spearman rank correlation coefficient between the extent of CB and $CL_{int, RMs}$ was 0.77 ($p < 0.0001$), which was better than that for the formation rates of [³⁵S]GS adducts. We therefore demonstrated that a combination of the [³⁵S]GSH trapping and TDI assays is an effective method for detecting compounds potentially capable of generating highly reactive metabolites in the early stages of drug discovery.

DMD #39180

Introduction

The metabolic activation of a compound to form a reactive metabolites (RMs) that undergo covalent binding (CB) to cellular macromolecules is considered to be an undesirable property for a drug (Kaplowitz, 2005; Baillie, 2006; Uetrecht, 2007). Current hypotheses based on retrospective studies suggest that metabolism to form RMs is an initial step in many drug-induced adverse events, such as direct damage to target organs or immune-mediated toxicity, that are involved in idiosyncratic drug toxicity (IDT). IDT occurs in rare cases and is generally manifested as severe hepatotoxicity, agranulocytosis, or other illnesses (Uetrecht, 2001). Many pharmaceutical companies now perform an assay for CB to assess the risk of a compound producing an adverse event (Reese et al., 2010 ; Thompson et al., 2010; Uetrecht, 2001; Evans et al., 2004; Obach et al., 2008; Bauman et al., 2009; Nakayama et al., 2009; Usui et al., 2009).

The current gold-standard approach for reliable quantification of the extent to which RMs covalently bind to proteins is the CB assay using radiolabeled compounds. However, during the process of lead optimization, the CB assay, because of its low throughput and high costs, is unsuitable for assessing whether lead compounds are liable to undergo bioactivation. Pharmaceutical companies have therefore made considerable efforts to develop alternative methods with higher throughputs. Trapping methods using [³⁵S]glutathione (GSH), K¹⁴CN, or the fluorescent dansylate analogue of GSH have been established for semiquantitative assessment of the bioactivation potential of compounds (Evans et al., 2004; Inoue et al., 2009; Kumar et al., 2009; Tang and Lu, 2010). Several reports have shown the existence of a positive correlation between the extent of CB and the rate of adduct formation of the trapping agent. For example, Takakusa et al.

DMD #39180

demonstrated a good correlation between them within a single series of derivatives by using [³⁵S]GSH as the trapping agent (Takakusa et al., 2009). Meneses-Lorente et al. obtained a similar result for piperidine-containing compounds by using K¹⁴CN as the trapping agent (Meneses-Lorente et al., 2006).

However, trapping methods alone cannot replace the CB assay, because methods that use nucleophiles can only detect RMs that have the opportunity to diffuse into the incubation medium from the active site of the enzyme. We hypothesized that mechanism-based inhibition (MBI), which is caused by the binding of short-lived RMs to the active site of the enzymes and is detected in time-dependent inhibition (TDI) assays, could be complementary to trapping methods. There are some reports regarding TDI and the extent of CB. For example, bergamottin is a mechanism-based inhibitor of the enzymes, CYP3A4, 1A2, 2B6, 2C9, and 2C19. When ¹⁴C-labeled bergamottin was incubated with membrane preparations of individual human recombinant P450 enzymes, the extent of CB correlated well with the inhibitory potentials of these enzymes (Kumar et al., 2009). On the basis of this result, a TDI assay might be capable of detecting RMs, and might provide a surrogate method for the overall assessment of bioactivation potential in advance of preparing labeled compounds for a CB assay.

In this study, we investigated the relationships between the formation rate of [³⁵S]GS adducts, the enzyme inactivation rate in the TDI assay, and the extent of CB in human liver microsomes (HLMs) for 42 structurally diverse marketed compounds to clarify whether the incorporation of TDI assays would result in improved accuracy in detection of RMs.

DMD #39180

Materials and Methods

Materials

A total of 42 radiolabeled compounds were used. Amodiaquine, benzbromarone, carbamazepine, clozapine, clopidogrel, donepezil, flutamide, furosemide, imipramine, nevirapine, olanzapine, pioglitazone, rosiglitazone, sulfamethoxazole, tienilic acid, tacrine, valsartan, zafirlukast, and zomepirac (all ^{14}C -labeled) were obtained from BlyChem Ltd. (Billingham, UK). Levofloxacin, olmesartan, pravastatin, and ticlopidine (all ^{14}C -labeled) were obtained from Sekisui Medical Co., Ltd. (Ibaraki, Japan). ^{14}C -labeled atorvastatin was obtained from MDS Pharma Services (Montreal, QC, Canada). Celecoxib and warfarin (both ^{14}C -labeled), and propranolol and tamoxifen (both ^3H -labeled) were purchased from GE Healthcare (Little Chalfont, UK). Acetaminophen, aminopyrine, caffeine, diclofenac, erythromycin, procainamide, and valproic acid (all ^{14}C -labeled), and ethinylestradiol and fluoxetine (both ^3H -labeled) were purchased from American radiolabeled Chemicals, Inc. (St. Louis, MO). Indomethacin and phenytoin (both ^{14}C -labeled), and ^3H -labeled verapamil were purchased from PerkinElmer (Boston, MA). ^{14}C -labeled amlodipine and ^3H -labeled ritonavir were purchased from Moravek Biochemicals (Brea, CA). The specific activities of ^{14}C -labeled compounds were in the range 13–58 mCi/mmol. ^3H -labeled compounds were diluted with their unlabeled compounds to give a final specific activity of 200 mCi/mmol. Unlabeled acetaminophen, amodiaquine, benzbromarone, carbamazepine, clozapine, diclofenac, erythromycin, ethinylestradiol, fluoxetine, flutamide, furosemide, imipramine, indomethacin, phenytoin, propranolol, sulfamethoxazole, tacrine, tamoxifen, ticlopidine, verapamil, warfarin, and zomepirac were obtained from Sigma (St. Louis, MO). Unlabeled aminopyrine, amlodipine, and valproic acid were purchased from Wako Pure Chemical Industries, Ltd.

DMD #39180

(Osaka, Japan). Unlabeled nevirapine, olanzapine, and ritonavir were purchased from Toronto Research Chemicals Inc. (North York, ON, Canada). Unlabeled caffeine and zafirlukast were obtained from Fluka (Buchs, Switzerland) and Cayman Chemical (Ann Arbor, MI), respectively. Unlabeled atorvastatin, celecoxib, clopidogrel, donepezil, levofloxacin, olmesartan, pioglitazone, pravastatin, procainamide, rosiglitazone, tienilic acid, and valsartan were synthesized by Daiichi Sankyo Co., Ltd. Pooled HLMs (n = 50, mixed gender) were purchased from XenoTech (Lenexa, KS). [³⁵S]GSH was purchased from PerkinElmer (Buchs, Switzerland). Phenacetin was purchased from Wako Pure Chemical (Osaka, Japan). Acetaminophen, paclitaxel, tolbutamide, dextromethorphan, and dextropran were purchased from Sigma (St. Louis, MO). Midazolam was purchased from Ultrafine (Manchester, UK). Bupropion, hydroxytolbutamide, (*S*)-mephénytoin, (±)-4'-hydroxymephénytoin, and 1'-hydroxymidazolam were purchased from BD Gentest (Franklin Lakes, NJ). (±)-Hydroxybupropion was purchased from Toronto Research Chemicals Inc (North York, ON, Canada). β-NADP⁺ and glucose-6-phosphate dehydrogenase (G6PDH) were purchased from Oriental Yeast Co., Ltd. (Tokyo, Japan), and glucose-6-phosphate (G6P) was obtained from Sigma (St. Louis, MO). All other reagents and solvents were of the highest grade commercially available.

CB assay using HLMs

The experimental procedure was based on that used in previously reported studies (Evans et al., 2004; Masubuchi et al., 2007). The experiments were performed in triplicate. The incubation mixture consisted of the following: 10 μM radiolabeled test compound (substrate), 2 mg/mL HLMs, 0.1 M potassium phosphate buffer (pH 7.4), 25 mM G6P, 2 units/mL G6PDH, and 10 mM MgCl₂. The mixture was preincubated for 3 min at 37 °C.

DMD #39180

Reaction was initiated by the addition of β -NADP⁺ to reach a final concentration of 2.5 mM, and the final incubation volume was 0.5 mL. As the substrates were dissolved in acetonitrile, the final incubation mixture contained 1% v/v acetonitrile. Radiolabeled compounds of at least 95% purity were used. After incubation of the mixture for 1 h, the reaction was terminated by the addition of ice-cold acetonitrile (0.5 mL). The mixture was then vortexed, sonicated in an ultrasonic bath, and centrifuged. The precipitated protein was washed twice with each of the following solvents in sequence: 80% (v/v) aqueous methanol containing 10% (w/v) trichloroacetic acid, diethyl ether–methanol (1:1, v/v), and 80% aqueous methanol. The resulting precipitated protein was dissolved in 0.5 mL of 1.0 M NaOH. Aliquots were taken for protein assay with a DC Protein Assay Kit (Bio-Rad Laboratories, Hercules, CA) and also for the determination of radioactivity by using a liquid scintillation counter after mixing the aliquot with Hionic-Fluor scintillation cocktail (PerkinElmer, Wellesley, MA). The amount of the test drug-related material as radioactivity covalently bound to the microsomal protein was calculated as a measure of the extent of CB (pmol/mg protein).

[³⁵S]GSH trapping assay

The experimental procedure was based on that used in a previously reported study (Takakusa et al., 2009). Each test compound was dissolved in acetonitrile–methanol (9:1, v/v) or acetonitrile–water (1:1, v/v) to prepare 10 mM stock solution. Each test compound (100 μ M) was then incubated at 37 °C with HLMs (2 mg/mL protein), and an NADPH-generating system in 0.1 M potassium phosphate buffer (pH7.4) supplemented with [³⁵S]GSH (0.2 mM, 925 kBq/test). The final reaction mixture contained 25 mM G6P, 2 units/mL G6PDH, and 10 mM MgCl₂. Reaction was initiated by the addition of

DMD #39180

β -NADP⁺ to reach a final concentration of 2.5 mM after a 3-min preincubation at 37 °C. The final incubation volume was 0.5 mL. A sample containing vehicle solution (9:1 acetonitrile–methanol or 1:1 acetonitrile–water) without substrate was used as a negative control. After 30 min incubation, the reaction was terminated by the addition of ice-cold acetonitrile (0.5 mL). The sample was centrifuged at 2000g for 15 min at 4 °C and then the supernatant was concentrated to approximately 0.1 mL by using a centrifuge evaporator. The concentrated sample (50 μ L) was analyzed by radio-HPLC using a Shimadzu LC-10Avp HPLC system (Kyoto, Japan) with an online radioactivity detector (RAD) (β -RAM model 3, IN/US Systems, Tampa, FL). The HPLC system was equipped with a 4.6 mm I.D. \times 150 mm (5 μ m) column (TSKgel ODS-100V, TOSOH, Tokyo, Japan) coupled with a 3.2 \times 15 mm (5 μ m) guard column (TSKguardgel ODS-100V, TOSOH). The sample was separated by using linear-gradient conditions at a flow rate of 1 mL/min. Ecoscint Flow (National Diagnostics, Atlanta, GA) was used as the scintillation fluid cocktail at a flow rate of 1 mL/min. The [³⁵S]GS adduct peaks were identified by visual comparison of radiochromatograms from the samples incubated with the individual test compound and a negative control. The sum of the radioactivity counts of the [³⁵S]GS adduct peaks (Area_{GS} [counts]) was calculated by using the computer software Laura 3.1 (LabLogic Systems, Sheffield, UK). The formation rate of [³⁵S]GS adducts was calculated by means of the following equation:

$$\text{formation rate of the } [^{35}\text{S}]\text{GS adducts } [\text{pmol}/\text{min}/\text{mg protein}] \\ = \text{Area}_{\text{GS}}/\text{Area}_{\text{total}} \times \text{the total amount of GSH } [\text{pmol}]/ \text{the reaction time } [\text{min}]/\text{the amount} \\ \text{of HLMs protein } [\text{mg protein}]$$

The total amount of GSH was 100,000 pmol, the reaction time was 30 min, and the amount of HLMs protein was 1 mg protein. Area_{total} [counts] expresses the total

DMD #39180

radioactivity counts observed on the radiochromatogram, calculated by means of the following equation:

$$\text{Area}_{\text{total}} = \text{Radioactivity injected [dpm]} \times f [\text{counts/dpm}]$$

The correction constant f [counts/dpm] was calculated by dividing the total radioactivity counts observed on the radiochromatogram of a 1:20 diluted sample by its radioactivity [dpm]. A liquid scintillation counter (TRI-CARB 2900TR, PerkinElmer) was used to measure the radioactivity [dpm] of the sample. The lower limit of quantification in each assay was set at the value of the formation rate of [^{35}S]GS adducts of diclofenac, which was obtained from each assay.

TDI assay

The experimental procedure was based on that used in a previously reported study (Watanabe et al., 2007). The TDI assay was automated by using a Beckman Biomek FX (Beckman Coulter Inc., Fullerton, CA). The preincubation solution contained 0.5 (for CYP3A4), 1.0 (for CYP1A2, 2B6, 2C8, 2C9 and 2D6) or 2.0 (for CYP2C19) mg/mL HLMS. The probe substrate and their final concentration were as follows: 50 μM phenacetin for CYP1A2, 50 μM bupropion for CYP2B6, 10 μM paclitaxel for CYP2C8, 200 μM tolbutamide for CYP2C9, 50 μM (*S*)-mephenytoin for CYP2C19, 30 μM dextromethorphan for CYP2D6, or 2.5 μM midazolam for CYP3A4. The preincubation and incubation solutions contained 0.1 M sodium phosphate buffer. The preincubation solution (178 μL) was transferred into the wells of the assay plate, and then 2 μL of a test compound solution or control solution (10% v/v dimethyl sulfoxide) was added. The concentration of each test compound was initially set at 100 μM . When the reversible inhibition of the compound was strong (percentage of control_(0 min) < 50%), it was diluted

DMD #39180

to a suitable concentration, as listed in Table 1. The preincubation reactions were initiated by the addition of 20 μL of an NADPH-generating system consisting of 25 mM $\beta\text{-NADP}^+$, 250 mM G6P, 20 units/mL G6PDH, and 100 mM MgCl_2 . The final volume of the preincubation mixture was 200 μL . For the 0-min preincubation, 20 μL of each preincubation mixture was immediately transferred into 180 μL of the incubation solution and then incubated for 10 min. For the 30-min preincubation, each preincubation mixture was diluted ten-fold with the incubation solution after 30 min. At the end of the incubation reactions, 50 μL aliquots of each incubation solution were added to 200 μL of methanol containing an internal standard. The samples were filtered through Captiva (Varian, Inc., Lake Forest, CA). All samples were analyzed by a liquid chromatography mass spectrometry (LC/MS) system consisting of an API 4000 (Applied Biosystems, Foster City, CA) with Shimadzu HPLC pumps and autosampler systems. Chromatographic separation was performed with Capcell Pak C18 MGII (S-5 μm , 2.0 mm I.D. \times 100 mm, Shiseido Co., Ltd., Tokyo, Japan). The percentages of the metabolic activity (percentage of control_(0 min) and percentage of control_(30 min)) was obtained for each sample after a 0-min or 30-min preincubation with an inhibitor, by comparison with the control sample after a 0 min or 30 min of preincubation without an inhibitor, as follows:

$$\text{Percentage of control}_{(0 \text{ min})} = v_{(0 \text{ min}, +\text{inhibitor})}/v_{(0 \text{ min}, -\text{inhibitor})} \times 100$$

$$\text{Percentage of control}_{(30 \text{ min})} = v_{(30 \text{ min}, +\text{inhibitor})}/v_{(30 \text{ min}, -\text{inhibitor})} \times 100$$

where, $v_{(0 \text{ min}, \pm \text{inhibitor})}$ is the metabolic activity after a 0-min preincubation with (+) or without (–) an inhibitor, and $v_{(30 \text{ min}, \pm \text{inhibitor})}$ is the metabolic activity after a 30-min preincubation with (+) or without (–) an inhibitor. By using these values, the percentage of enzyme inactivation after 30 min of preincubation relative to that after 0 min of preincubation was calculated as follows:

DMD #39180

Percentage of enzyme inactivation = $100 \times [1 - \text{percentage of control}_{(30 \text{ min})} / \text{percentage of control}_{(0 \text{ min})}]$

The threshold for percentage of enzyme inactivation in each assay was set at 10%.

Calculation of the enzyme inactivation rate

The percentage of enzyme inactivation was transformed into the enzyme inactivation rate by correcting for the incubation time and the contents of each isoform. The following equation was used to calculate the enzyme inactivation rate in each of the tested CYP isoforms:

Enzyme inactivation rate [nmol/min/mg protein]
= percentage of enzyme inactivation \times contents of each isoform [nmol/mg protein]/preincubation time [min]

The values for the contents of each isoform were taken from Simcyp version 8.0 (Simcyp Ltd., UK) as follows: CYP1A2: 52, CYP2B6: 17, CYP2C8: 24, CYP2C9: 73, CYP2C19: 14, CYP2D6: 8, and CYP3A4: 142 pmol/mg protein. The preincubation time was 30 min. The sum of the rates of inactivation of all the tested CYP isoforms was calculated.

Calculations of the combined intrinsic clearance for forming RMs based on the formation rate of [³⁵S]GS adducts and the enzyme inactivation rate in the TDI assay

The formation rate of [³⁵S]GS adducts and the enzyme inactivation rate in TDI assay were transformed into an intrinsic clearance for forming RMs by correcting for the concentration of each tested compounds in the test systems by assuming that each enzyme reaction is linear and that the enzyme inactivation rate is equal to the formation rate of the RMs. The following equation was used to calculate the combined intrinsic clearance for

DMD #39180

forming RMs ($CL_{int, RMs}$):

$CL_{int, RMs}$ [$\mu\text{L}/\text{min}/\text{mg}$ protein]

= $CL_{int, RMs (GSH)} + CL_{int, RMs (TDI)}$

= formation rate of the [^{35}S]GS adducts [$\text{pmol}/\text{min}/\text{mg}$ protein]/substrate concentration

[μM] + enzyme inactivation rate in each isoform [$\text{pmol}/\text{min}/\text{mg}$ protein]/tested

concentration in preincubation in TDI assay [μM]

where, $CL_{int, RMs (GSH)}$ is the intrinsic clearance for forming RMs calculated from the

formation rate of [^{35}S]GS adducts and $CL_{int, RMs (TDI)}$ is the intrinsic clearance for forming

RMs calculated from the enzyme inactivation rate in TDI assay.

Classification of the tested compounds on the basis of the results of the [^{35}S]GSH trapping assay and the TDI assay

The compounds were classified into four groups on the basis of the quantitative results of the [^{35}S]GSH trapping assay and the TDI assay. Compounds that show detectable [^{35}S]GS adduct peaks were defined as positive in the [^{35}S]GSH trapping assay. Compounds that showed a percentage of enzyme inactivation of more than 10% in at least one isoform in the TDI assay were defined as positive in the TDI assay. Group 1 consisted of compounds that were judged as negative in both assays, Group 2 consisted of compounds that were judged as positive in the TDI assay only, Group 3 consisted of compounds that were judged as positive in the [^{35}S]GSH trapping assay only, and Group 4 consisted of compounds that were judged as positive in both assays.

Statistical analysis

Statistical analyses were performed with SAS System Release 8.2 (SAS Institute Inc.).

DMD #39180

Spearman rank correlation coefficients were calculated to evaluate the relation between the rates of formation of [^{35}S]GS adducts and the extent of CB (Figure 1), between the enzyme inactivation rates and the extent of CB (Figure 2), and between the values of CL_{int} , RMs and the extent of CB (Figure 3). In relation to the extent of CB, the Wilcoxon rank-sum test was performed for group comparison between Groups 1 and 2, 1 and 3, 1 and 4, 2 and 4, and 3 and 4; a value of $p < 0.05$ was considered to be statistically significant (Table 2).

DMD #39180

Results

The extent of CB in HLMs, the formation rate of [³⁵S]GS adducts, and the percentage of enzyme inactivation in the TDI assay

A summary of the extent of CB in HLMs, the formation rate of [³⁵S]GSH adducts, and the percentage of enzyme inactivation in the TDI assay with the previous reports on GSH adduct formation, MBI or TDI as references is presented in Table 1. With the exception of levofloxacin, all the compounds showed measurable degrees of CB. The extent of CB of the tested compounds ranged from 1.4 pmol/mg protein for valsartan to 937.5 pmol/mg protein for ethinylestradiol. The extent of CB was more than 50 pmol/mg for 19 compounds. 50 pmol/mg was a target maximum value for CB in selecting drug candidates for entry into development as reported by the Merck group (Evans et al., 2004). [³⁵S]GS adduct peaks were detected for 21 compounds, with formation rates ranging from 1.0 pmol/min/mg protein for diclofenac to 43.1 pmol/min/mg protein for ticlopidine. The other 21 compounds did not show measurable [³⁵S]GS adduct peaks in their radiochromatograms. The concentrations of the test compounds ranged from 0.1 to 100 μ M in the TDI assay, depending on the strength of reversible inhibition. Enzymes CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4 were inactivated by 9, 4, 1, 2, 5, 3, and 11 compounds, respectively. Twenty-one compounds did not inactivate any isoform of the tested CYP enzyme.

Relationship between the formation rate of [³⁵S]GS adducts and the extent of CB in HLMs

To investigate the relationship between the formation rate of [³⁵S]GS adducts and the extent of the CB in HLMs, the logarithm of the extent of CB was plotted against the logarithm of the formation rate of [³⁵S]GS adducts (Figure 1). The Spearman rank

DMD #39180

correlation coefficients (r) between the formation rate of [^{35}S]GS adducts and the extent of the CB was calculated to be 0.50 ($p = 0.0008$). Four compounds (erythromycin, pioglitazone, ritonavir, and tacrine) that showed an extent of CB of more than 50 pmol/mg protein did not show detectable [^{35}S]GS adduct peaks.

Relationship between the enzyme inactivation rate in the TDI assay and the extent of CB in HLMs

To consider the enzyme inactivation for all the tested CYP isoforms together, the percentage of enzyme inactivation was corrected for the incubation time and the contents of the isoform, and the enzyme inactivation rate was calculated. The logarithm of the extent of CB was plotted against the logarithm of the sum of each enzyme inactivation rate (Figure 2). Erythromycin, pioglitazone, ritonavir, and tacrine, which did not show a detectable [^{35}S]GS adduct peak (Figure 1), did inactivate the CYP enzyme. However, the extent of CB was not correlated with the enzyme inactivation rate ($r = 0.14$, $p = 0.37$). Furthermore, six compounds with CB of more than 50 pmol/mg protein did not show inactivation of any of the tested CYP isoforms.

Classification of the tested compounds on the basis of the results of the [^{35}S]GSH trapping assay and the TDI assay

The tested compounds were classified into four groups on the basis of the combined results of the GSH trapping and TDI assays. Compounds that show a detectable [^{35}S]GS adduct peaks were defined as positive in the GSH trapping assay. Compounds that showed more than 10% enzyme inactivation (Table 1) in at least one isoform in the TDI assay were defined as TDI positive. The list of the compounds and the mean values \pm standard

DMD #39180

deviations, minima, and maxima in the extent of CB in each group are shown in Table 2. Group 1 consists of 11 compounds that showed negative results in both the GSH trapping and TDI assays (–/–); similarly, Group 2 (–/+), Group 3 (+/–), and Group 4 (+/+) contained 10, 10, and 11 compounds, respectively. Group 1 showed a significantly lower extent of CB than did Group 2 and Group 3 ($p = 0.001$ and 0.02 , respectively). Group 4 showed a significantly higher extent of CB than did Group 2 ($p = 0.01$). Although not statistically significant ($p = 0.053$), the average value of the extent of CB in Group 4 (353 pmol/mg protein) was higher than that of Group 3 (104 pmol/mg protein).

Relationship between the combined intrinsic clearance for forming RMs and the extent of CB

The $CL_{int, RMs}$ were calculated based on the formation rates of [^{35}S]GS adducts and CYP enzyme inactivation rates (Table 3). The logarithm extent of the CB was plotted against the $CL_{int, RMs}$ (Figure 3). The Spearman rank correlation coefficient was 0.77 ($p < 0.0001$).

DMD #39180

Discussion

In a previous study, we established a zone classification system that uses the extent of CB in human hepatocytes and the daily dose to assess the risks of IDT (Nakayama et al., 2009). It is clear from our previous result that both the extent of the CB and the daily dose are risk factors for IDT. From a practical point of view, because the efficacious daily dose cannot be easily determined in the early stages of drug discovery, experimental approaches to minimize the risk of bioactivation should be used to minimize the risk of toxicity. However, because of its low throughput and high costs, the CB assay is unsuitable for use as a bioactivation assay during the process of lead optimization.

The [³⁵S]GSH trapping assay, which is often used to detect RMs, has the advantages that it does not require radiolabeled compounds and that it provides quantitative information on the formation of RMs. However trapping methods alone cannot replace the CB assay. We hypothesized that the TDI assay might be complementary to the [³⁵S]GSH trapping assay in detecting RMs.

First, we showed that the [³⁵S]GSH trapping assay alone failed to show good correlation with extent of CB (Figure 1). Then, as expected from our hypothesis, four compounds (erythromycin, pioglitazone, ritonavir, and tacrine) that the [³⁵S]GSH trapping assay failed to detect, but which showed a high extent of CB, were inactivators of the CYP enzyme (Figure 2). Furthermore, there was a tendency for compounds that were judged as positive in the TDI assay to show a high degree of the extent of CB, irrespectively of the results of the [³⁵S]GSH trapping assay (Table 2). As mentioned in the Introduction, a

DMD #39180

mechanism-based inactivator is not easily attenuated by trapping agents; this is probably the result of rapid CB of highly reactive species at the active site of the enzyme before they have the opportunity to diffuse away from the active site and react with the trapping agent (Silverman, 1995; Kalgutkar et al., 2007). To combine the parameters from the [³⁵S]GSH trapping assay with those from the TDI assay, we introduced a new parameter, $CL_{int, RMs}$ (Table 3). As shown in Figure 3, the Spearman rank correlation coefficients between $CL_{int, RMs}$ and the extent of CB was 0.77 ($p < 0.0001$), which is a better value than that of the formation rate of [³⁵S]GS adducts. Our results show that we can assess the risk of a compound forming RMs by using a combination of [³⁵S]GSH trapping and TDI assays in the early stages of drug discovery; these methods have a relatively high throughput and do not require the use of radiolabeled compounds.

$CL_{int, RMs}$ was calculated by assuming that each enzyme reaction is linear and that the enzyme inactivation rate is equal to the rate of formation of RMs. However, the enzyme inactivation rate is proportional at the low concentration of the inactivator, and it can be saturated at high concentrations. Furthermore, TDI not only occurs by the protein-alkylation mechanism but also by quasi-irreversible or heme alkylation (Riley et al., 2007; Hollenberg et al., 2008). For example, the mechanism of inhibition by some of the tested compounds, such as amlodipine, erythromycin, and verapamil, is reported to be quasi-irreversible inhibition (Grimm et al., 2009). RMs that cause TDI by quasi-irreversible inhibition or heme alkylation are not detected in the CB assay.

And, some type of RMs generated in the incubations are not either bound to the CYP enzyme responsible for their formation (causing TDI) or are trapped by GSH. For example,

DMD #39180

GSH cannot trap some types of “hard” RMs, such as iminium ions, radical species, or aldehydes (Kumar et al., 2008; Kumar et al., 2009). Inoue et al. showed that a combination of the trapping reagents [³⁵S]cysteine and K¹⁴CN improved accuracy in the detection of compounds with a high extent of CB (Inoue et al., 2009). Thus, calculating the CL_{int, RMs} may be a rough estimation of the extent of CB. However because our results shows relatively good correlation between the extent of CB and CL_{int, RMs} calculated from the result of [³⁵S]GSH trapping and TDI assays, we consider that the most of RMs could be detected by these two assays. And that this approach is useful in the early stages of drug discovery.

In this study, pioglitazone, tacrine, and erythromycin did not show measurable [³⁵S]GS adduct peaks in their radiochromatograms in [³⁵S]GSH trapping assay in spite of higher extent of CB. The mechanisms of generation of RMs from these compounds are known to be S-oxidation (pioglitazone) or the formation of a quinone methide (tacrine) or a nitroso moiety (erythromycin) (Larrey et al., 1983; Madden et al., 1993; Alvarez-Sanchez et al., 2006). Generally, these RMs could be trapped by GSH, and actually the formation of GSH adduct of pioglitazone and tacrine using LC/MS were reported (Lim et al., 2005, Zhang and Yang, 2008). The reason for the difference in the results seemed to be sensitivity of the detection, because the information using LS/MS is of qualitative nature only (Kumar et al., 2009). The RMs of pioglitazone and tacrine would be trapped using [³⁵S]GSH, but the amount of the [³⁵S]GS adducts would be lower than the limit of quantification. On the other hands, based on the result of TDI assays, these RMs would be short-lived to the active site of the enzymes and cause TDI. Thus, we consider that most parts of the RMs of these compounds would be bound to the CYP active site, and a few RMs would diffuse

DMD #39180

away from the active site and react with the GSH.

Recently, some studies, including our own previous study, have reported that the CB of drugs in human hepatocytes shows the best correlation with their safety profiles (Bauman et al., 2009; Nakayama et al., 2009; Usui et al., 2009). The results of these studies showed that metabolism, which does not occur in HLMs with NADPH, is also an important factor. Examples involve the acyl glucuronides of zomepirac (Wang et al., 2001) and valproic acid (Kumar et al., 2000), and the β -oxidation of valproic acid (Baillie, 1992). In this study, zomepirac and valproic acid were not assessed as having a positive risk of forming RMs in either the [³⁵S]GSH trapping assay or the TDI assay. It is therefore difficult to make a complete assessment of the risk of formation of RMs by using HLMs. However, in terms of throughput and handling, HLMs provide a suitable enzyme source for the preliminary assessment of the potential risks of generating highly reactive metabolites.

In summary, we have demonstrated that a combination of the [³⁵S]GSH trapping assay and the TDI assay is an effective method for detecting compounds potentially capable of generating highly reactive metabolites in the early stages of drug discovery.

DMD #39180

Authorship Contributions

Participated in research design: Nakayama, Takakusa, Watanabe, and Okazaki

Conducted experiments: Nakayama, Miyaji, Watanabe, and Suzuki

Performed data analysis: Sugiyama, Shiosakai, Honda

Wrote or contributed to the writing of the manuscript: Nakayama, Okudaira, Isumi, and Okazaki

References

- Alvarez-Sanchez R, Montavon F, Hartung T and Pahler A (2006) Thiazolidinedione bioactivation: a comparison of the bioactivation potentials of troglitazone, rosiglitazone, and pioglitazone using stable isotope-labeled analogues and liquid chromatography tandem mass spectrometry. *Chem Res Toxicol* **19**:1106-1116.
- Baillie TA (1992) Metabolism of valproate to hepatotoxic intermediates. *Pharm Weekbl Sci* **14**:122-125.
- Baillie TA (2006) Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology. *Chem Res Toxicol* **19**:889-893.
- Bauman JN, Kelly JM, Tripathy S, Zhao SX, Lam WW, Kalgutkar AS and Obach RS (2009) Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction. *Chem Res Toxicol* **22**:332-340.
- Chang SY, Chen C, Yang Z and Rodrigues AD (2009) Further assessment of 17alpha-ethinyl estradiol as an inhibitor of different human cytochrome P450 forms in vitro. *Drug Metab Dispos* **37**:1667-1675.
- Coles B, Wilson I, Wardman P, Hinson JA, Nelson SD and Ketterer B (1988) The spontaneous and enzymatic reaction of N-acetyl-p-benzoquinonimine with glutathione: a stopped-flow kinetic study. *Arch Biochem Biophys* **264**:253-260.
- Cribb AE, Miller M, Leeder JS, Hill J and Spielberg SP (1991) Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione. Implications for idiosyncratic toxicity. *Drug Metab Dispos* **19**:900-906.
- Dansette PM, Libraire J, Bertho G and Mansuy D (2009) Metabolic oxidative cleavage of thioesters: evidence for the formation of sulfenic acid intermediates in the bioactivation of the antithrombotic prodrugs ticlopidine and clopidogrel. *Chem Res Toxicol* **22**:369-373.
- Evans DC, Watt AP, Nicoll-Griffith DA and Baillie TA (2004) Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. *Chem Res Toxicol* **17**:3-16.
- Grimm SW, Einolf HJ, Hall SD, He K, Lim HK, Ling KH, Lu C, Nomeir AA, Seibert E, Skordos KW, Tonn GR, Van Horn R, Wang RW, Wong YN, Yang TJ and Obach RS (2009) The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America. *Drug Metab Dispos* **37**:1355-1370.
- Hollenberg PF, Kent UM and Bumpus NN (2008) Mechanism-based inactivation of human cytochromes p450s: experimental characterization, reactive intermediates, and clinical implications. *Chem Res Toxicol* **21**:189-205.
- Inoue K, Shibata Y, Takahashi H, Ohe T, Chiba M and Ishii Y (2009) A trapping method for semi-quantitative assessment of reactive metabolite formation using [³⁵S]cysteine and [¹⁴C]cyanide. *Drug Metab Pharmacokinet* **24**:245-254.
- Jean P, Lopez-Garcia P, Dansette P, Mansuy D and Goldstein JL (1996) Oxidation of tienilic acid by human yeast-expressed cytochromes P-450 2C8, 2C9, 2C18 and 2C19. Evidence that this drug is a mechanism-based inhibitor specific for cytochrome P-450 2C9. *Eur J Biochem* **241**:797-804.
- Ju C and Utrecht JP (1998) Oxidation of a metabolite of indomethacin (Desmethyl-deschlorobenzoylindomethacin) to reactive intermediates by activated neutrophils, hypochlorous acid, and the myeloperoxidase system. *Drug Metab*

- Dispos* **26**:676-680.
- Kalgutkar AS, Obach RS and Maurer TS (2007) Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions. *Curr Drug Metab* **8**:407-447.
- Kang P, Dalvie D, Smith E, Zhou S and Deese A (2007) Identification of a novel glutathione conjugate of flutamide in incubations with human liver microsomes. *Drug Metab Dispos* **35**:1081-1088.
- Kaplowitz N (2005) Idiosyncratic drug hepatotoxicity. *Nat Rev Drug Discov* **4**:489-499.
- Kassahun K, Skordos K, McIntosh I, Slaughter D, Doss GA, Baillie TA and Yost GS (2005) Zafirlukast metabolism by cytochrome P450 3A4 produces an electrophilic alpha,beta-unsaturated iminium species that results in the selective mechanism-based inactivation of the enzyme. *Chem Res Toxicol* **18**:1427-1437.
- Kent UM, Lin HL, Mills DE, Regal KA and Hollenberg PF (2006) Identification of 17-alpha-ethynylestradiol-modified active site peptides and glutathione conjugates formed during metabolism and inactivation of P450s 2B1 and 2B6. *Chem Res Toxicol* **19**:279-287.
- Kumar S, Kassahun K, Tschirret-Guth RA, Mitra K and Baillie TA (2008) Minimizing metabolic activation during pharmaceutical lead optimization: progress, knowledge gaps and future directions. *Curr Opin Drug Discov Devel* **11**:43-52.
- Kumar S, Mitra K, Kassahun K and Baillie TA (2009) Approaches for minimizing metabolic activation of new drug candidates in drug discovery. *Handb Exp Pharmacol*:511-544.
- Kumar S, Wong H, Yeung SA, Riggs KW, Abbott FS and Rurak DW (2000) Disposition of valproic acid in maternal, fetal, and newborn sheep. II: metabolism and renal elimination. *Drug Metab Dispos* **28**:857-864.
- Larrey D, Tinel M and Pessayre D (1983) Formation of inactive cytochrome P-450 Fe(II)-metabolite complexes with several erythromycin derivatives but not with josamycin and midecamycin in rats. *Biochem Pharmacol* **32**:1487-1493.
- Lim HK, Duczak N, Jr., Brougham L, Elliot M, Patel K and Chan K (2005) Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes. *Drug Metab Dispos* **33**:1211-1219.
- Liu ZC and Utrecht JP (2000) Metabolism of ticlopidine by activated neutrophils: implications for ticlopidine-induced agranulocytosis. *Drug Metab Dispos* **28**:726-730.
- Luo G, Lin J, Fiske WD, Dai R, Yang TJ, Kim S, Sinz M, LeCluyse E, Solon E, Brennan JM, Benedek IH, Jolley S, Gilbert D, Wang L, Lee FW and Gan LS (2003) Concurrent induction and mechanism-based inactivation of CYP3A4 by an L-valinamide derivative. *Drug Metab Dispos* **31**:1170-1175.
- Madden S, Woolf TF, Pool WF and Park BK (1993) An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro. Studies with human and rat liver microsomes. *Biochem Pharmacol* **46**:13-20.
- Masubuchi N, Makino C and Murayama N (2007) Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediate: correlation of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugate formation in rats and humans. *Chem Res Toxicol* **20**:455-464.
- Masubuchi Y, Nakano T, Ose A and Horie T (2001) Differential selectivity in

DMD #39180

- carbamazepine-induced inactivation of cytochrome P450 enzymes in rat and human liver. *Arch Toxicol* **75**:538-543.
- Masubuchi Y, Ose A and Horie T (2002) Diclofenac-induced inactivation of CYP3A4 and its stimulation by quinidine. *Drug Metab Dispos* **30**:1143-1148.
- McDonald MG and Rettie AE (2007) Sequential metabolism and bioactivation of the hepatotoxin benzbromarone: formation of glutathione adducts from a catechol intermediate. *Chem Res Toxicol* **20**:1833-1842.
- Meneses-Lorente G, Sakatis MZ, Schulz-Utermoehl T, De Nardi C and Watt AP (2006) A quantitative high-throughput trapping assay as a measurement of potential for bioactivation. *Anal Biochem* **351**:266-272.
- Naisbitt DJ, Williams DP, O'Neill PM, Maggs JL, Willock DJ, Pirmohamed M and Park BK (1998) Metabolism-dependent neutrophil cytotoxicity of amodiaquine: A comparison with pyronaridine and related antimalarial drugs. *Chem Res Toxicol* **11**:1586-1595.
- Nakayama S, Atsumi R, Takakusa H, Kobayashi Y, Kurihara A, Nagai Y, Nakai D and Okazaki O (2009) A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding. *Drug Metab Dispos* **37**:1970-1977.
- Nishiya Y, Hagihara K, Ito T, Tajima M, Miura S, Kurihara A, Farid NA and Ikeda T (2009a) Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel. *Drug Metab Dispos* **37**:589-593.
- Nishiya Y, Hagihara K, Kurihara A, Okudaira N, Farid NA, Okazaki O and Ikeda T (2009b) Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel. *Xenobiotica*.
- Obach RS, Kalgutkar AS, Soglia JR and Zhao SX (2008) Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose. *Chem Res Toxicol* **21**:1814-1822.
- Reese M, Sakatis M, Ambroso J, Harrell A, Yang E, Chen L, Taylor M, Baines I, Zhu L, Ayrton A and Clarke S (2010) An integrated reactive metabolite evaluation approach to assess and reduce safety risk during drug discovery and development. *Chem Biol Interact.* (in press) doi:10.1016/j.cbi.2010.10.005.
- Riley RJ, Grime K and Weaver R (2007) Time-dependent CYP inhibition. *Expert Opin Drug Metab Toxicol* **3**:51-66.
- Rowland K, Yeo WW, Ellis SW, Chadwick IG, Haq I, Lennard MS, Jackson PR, Ramsay LE and Tucker GT (1994) Inhibition of CYP2D6 activity by treatment with propranolol and the role of 4-hydroxy propranolol. *Br J Clin Pharmacol* **38**:9-14.
- Silverman RB (1995) Mechanism-based enzyme inactivators. *Methods Enzymol* **249**:240-283.
- Stresser DM, Mason AK, Perloff ES, Ho T, Crespi CL, Dandeneau AA, Morgan L and Dehal SS (2009) Differential time- and NADPH-dependent inhibition of CYP2C19 by enantiomers of fluoxetine. *Drug Metab Dispos* **37**:695-698.
- Takakusa H, Masumoto H, Makino C, Okazaki O and Sudo K (2009) Quantitative assessment of reactive metabolite formation using ³⁵S-labeled glutathione. *Drug Metab Pharmacokinet* **24**:100-107.
- Tang W and Lu AY (2010) Metabolic bioactivation and drug-related adverse effects:

DMD #39180

- current status and future directions from a pharmaceutical research perspective. *Drug Metab Rev* **42**:225-249.
- Tang W, Stearns RA, Bandiera SM, Zhang Y, Raab C, Braun MP, Dean DC, Pang J, Leung KH, Doss GA, Strauss JR, Kwei GY, Rushmore TH, Chiu SH and Baillie TA (1999) Studies on cytochrome P-450-mediated bioactivation of diclofenac in rats and in human hepatocytes: identification of glutathione conjugated metabolites. *Drug Metab Dispos* **27**:365-372.
- Thompson RA, Isin EM, Li Y, Weaver R, Weidolf L, Wilson I, Claesson A, Page K, Dolgos H and Kenna JG (2010) Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development. *Chem Biol Interact* (in press) doi:10.1016/j.cbi.2010.11.002.
- Utrecht J (2001) Prediction of a new drug's potential to cause idiosyncratic reactions. *Curr Opin Drug Discov Devel* **4**:55-59.
- Utrecht J (2007) Idiosyncratic drug reactions: current understanding. *Annu Rev Pharmacol Toxicol* **47**:513-539.
- Utrecht JP (1985) Reactivity and possible significance of hydroxylamine and nitroso metabolites of procainamide. *J Pharmacol Exp Ther* **232**:420-425.
- Usui T, Mise M, Hashizume T, Yabuki M and Komuro S (2009) Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins. *Drug Metab Dispos* **37**:2383-2392.
- Wang M, Gorrell MD, McGaughan GW and Dickinson RG (2001) Dipeptidyl peptidase IV is a target for covalent adduct formation with the acyl glucuronide metabolite of the anti-inflammatory drug zomepirac. *Life Sci* **68**:785-797.
- Watanabe A, Nakamura K, Okudaira N, Okazaki O and Sudo K (2007) Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process. *Drug Metab Dispos* **35**:1232-1238.
- Wen B, Chen Y and Fitch WL (2009) Metabolic activation of nevirapine in human liver microsomes: dehydrogenation and inactivation of cytochrome P450 3A4. *Drug Metab Dispos* **37**:1557-1562.
- Williams DP, Pirmohamed M, Naisbitt DJ, Maggs JL and Park BK (1997) Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: possible role in agranulocytosis. *J Pharmacol Exp Ther* **283**:1375-1382.
- Yao D, Zhang F, Yu L, Yang Y, van Breemen RB and Bolton JL (2001) Synthesis and reactivity of potential toxic metabolites of tamoxifen analogues: droloxifene and toremifene o-quinones. *Chem Res Toxicol* **14**:1643-1653.
- Zhang H and Yang Y (2008) An algorithm for thorough background subtraction from high-resolution LC/MS data: application for detection of glutathione-trapped reactive metabolites. *J Mass Spectrom* **43**:1181-1190.

DMD #39180

Footnotes

Address correspondence to:

Shintaro Nakayama

Drug Metabolism and Pharmacokinetics Research Laboratories, R&D Division, Daiichi

Sankyo Co., Ltd.

1-2-58, Hiromachi, Shinagawa-ku, Tokyo, 140-8710, Japan.

tel: +81-538-42-4356 fax: +81-538-42-4350

E-mail: nakayama.shintaro.gg@daiichisankyo.co.jp

DMD #39180

Legends for figures

Figure 1. Log–log plot showing the relationship between the formation rate of [³⁵S]GS adducts and the extent of CB in HLMs.

Abbreviations: ERM, erythromycin, PGZ, pioglitazone; RTV, ritonavir; and TC, tacrine. For illustrational purposes, the horizontal dotted line is plotted at the 50 pmol/mg protein level in the extent of CB.

r is the Spearman rank correlation coefficient.

Figure 2. Log–log plot showing the relationship between the enzyme inactivation rate of all tested isoforms in the TDI assay.

Abbreviations: ERM, erythromycin, PGZ, pioglitazone; RTV, ritonavir; and TC, tacrine. For illustrational purposes, the horizontal dotted line is plotted at the 50 pmol/mg protein level in the extent of CB.

r is the Spearman rank correlation coefficient.

Figure 3. Log–log plot showing the relationship between the CL_{int, RM_s} and the extent of CB.

For illustrational purposes, the horizontal dotted line is plotted at the 50 pmol/mg protein level in the extent of CB.

r is the Spearman rank correlation coefficient.

DMD #39180

Table 1. The extent of CB in HLMS, the formation rate of the [³⁵S]GS adducts, and the percentage of enzyme inactivation in the TDI assay with the previous reports on GSH adduct formation, MBI or TDI as references.

| Compound | Extent of CB (pmol/mg protein) | Formation rate of [³⁵ S]GS adducts (pmol/mg protein) | TDI (percentage of CYP enzyme inactivation) | | | | | | | Reference |
|------------------|-----------------------------------|--|--|-----------------|----------------|-----------------|-----------------|----------------|-----------------|----------------------|
| | | | 1A2 | 2B6 | 2C8 | 2C9 | 2C19 | 2D6 | 3A4 | |
| Acetaminophen | 71.3 | 19.8 | - | - | - | - | - | - | - ^c | GSH; 1 |
| Aminopyrine | 30.9 | N.D. | - | - | - | - | - | - | - | |
| Amlodipine | 7.1 | N.D. | - | - ^d | - | - ^b | - | - | 42 | TDI; 2 |
| Amodiaquin | 208.1 | 2.1 | - | - | - ^b | - | - | - ^c | - | GSH; 3 |
| Atorvastatin | 352.3 | 12.7 | - | - | - | - | - | - | - | |
| Benzbromarone | 389.9 | 3 | 12 | - ^c | - ^d | - ^e | - | - | - ^c | GSH; 4 |
| Caffeine | 9.9 | N.D. | - | - | - | - | - | - | - | |
| Carbamazepine | 3.3 | N.D. | - | - | - | - | - | - | - ^c | TDI; 5 |
| Celecoxib | 13 | N.D. | - | - ^b | - | - ^b | - | - ^b | - ^c | |
| Clopidogrel | 417.4 | 23.6 | - | 44 ^f | - | - | 10 | - | 35 | GSH; 6, TDI; 7, 8 |
| Clozapine | 44.7 | 14.7 | 12 | - | - | - | - | - | 21 | GSH; 9, TDI; 2 |
| Diclofenac | 14.5 | 1 | - | - | - | - | - | - | - | GSH; 10, TDI; 11 |
| Donepezil | 29.7 | N.D. | - | - | - | - | - | 10 | - | |
| Erythromycin | 57.1 | N.D. | - | - | - | - | - | - | 45 | TDI; 2 |
| Ethinylestradiol | 937.5 | 34 | 18 | - ^b | - ^c | 27 ^b | - ^c | - | 65 ^a | GSH; 12, TDI; 12, 13 |
| Fluoxetine | 15 | N.D. | 12 | - | - | - | 36 ^b | - ^c | - | TDI; 14 |
| Flutamide | 178 | 2 | - | - | - | - | - | - | - | GSH; 15 |
| Furosemide | 73.9 | 7.2 | - | - | - | - | - | - | - | GSH; 16 |
| Imipramine | 133.8 | 1.2 | - | - | - | - | - | - | - | GSH; 16 |
| Indomethacin | 14.7 | N.D. | - | - | 14 | - | - | - | - | GSH; 17 |
| Levofloxacin | N.D. | N.D. | - | - | - | - | - | - | - | |
| Nevirapine | 19.1 | 1.2 | - | - | - | - | 12 | - | - | GSH and TDI; 18 |
| Olanzapine | 138.9 | 11.3 | - | - | - | - | - | 63 | - | |
| Olmesartan | 3.4 | N.D. | - | - | - | - | - | - | - | |
| Phenytoin | 4.4 | 1.2 | - | - | - | - | - | - | - | |
| Pioglitazone | 353 | N.D. | - | 38 | - ^b | - | - | - | 61 | GSH; 19,TDI;20 |
| Pravastatin | 3.7 | N.D. | - | - | - | - | - | - | - | |
| Procainamide | 5.1 | 41.3 | - | - | - | - | - | - | - | GSH; 21 |
| Propranolol | 70 | 2.7 | 25 | - | - | - | - | - | - | GSH and TDI;22 |
| Ritonavir | 253.3 | N.D. | - | - ^f | - ^c | - ^d | - ^c | - ^c | 75 ^e | TDI; 23 |
| Rosiglitazone | 516.1 | 2.2 | - | - | - ^c | - | - | - | 56 | GSH; 20,TDI;21 |
| Sulfamethoxazole | 3.2 | 21.3 | - | - | - | - | - | - | - | GSH; 24 |
| Tacrine | 137 | N.D. | 28 | - | - | - | - | 24 | - | GSH; 25, TDI, 26 |
| Tamoxifen | 11.5 | N.D. | - | - | - ^c | - | - | - | - | TDI; 27 |
| Ticlopidine | 851.9 | 43.1 | 36 | 35 ^g | - | - | 60 ^e | - ^c | 26 | GSH; 28, TDI; 7, 8 |
| Tienilic acid | 436.7 | 4.2 | - | - | - | 28 ^c | 35 | - | - | GSH; 16, TDI; 29 |
| Valproic acid | 6.3 | N.D. | - | - | - | - | - | - | - | |
| Valsartan | 1.4 | N.D. | - | - | - | - | - | - | - | |
| Verapamil | 65.6 | 4.8 | - | 10 | - | - | - | - | 51 | GSH; 16, TDI; 2 |
| Warfarin | 15.9 | N.D. | 19 | - | - | - | - | - | - | |
| Zafirlukast | 36.4 | N.D. | 11 | - ^c | - ^d | - ^c | - | - | 43 ^c | TDI; 30 |
| Zomepirac | 6.4 | N.D. | - | - | - | - | - | - | - | |

In TDI assay, the concentration of each test compound was initially set at 100 μM. For compounds with strong reversible inhibitory effects, the compounds were diluted to a suitable concentration as follows: a: 50 μM, b: 30 μM, c: 10 μM, d: 3 μM, e: 1 μM, f: 0.3 μM, g: 0.1 μM.

N.D.; not determined

-; percentage of CYP enzyme inactivation < threshold at 10 %

References; 1: (Coles et al., 1988), 2: (Watanabe et al., 2007), 3: (Naisbitt et al., 1998), 4: (McDonald and Rettie, 2007), 5: (Masubuchi et al., 2001), 6: (Dansette et al., 2009), 7: (Nishiya et al., 2009a), 8: (Nishiya et al., 2009b), 9: (Williams et al., 1997), 10: (Tang et al., 1999), 11: (Masubuchi et al., 2002), 12: (Kent et al., 2006), 13: (Chang et al., 2009), 14: (Stresser et al., 2009), 15: (Kang et al., 2007), 16:

DMD #39180

(Masubuchi et al., 2007), 17: (Ju and Uetrecht, 1998), 18: (Wen et al., 2009), 19:
(Alvarez-Sanchez et al., 2006), 20: (Lim et al., 2005), 21: (Uetrecht, 1985), 22:
(Rowland et al., 1994), 23: (Luo et al., 2003), 24: (Cribb et al., 1991), 25: (Zhang
and Yang, 2008), 26: (Kalgutkar et al., 2007), 27: (Yao et al., 2001), 28: (Liu and
Uetrecht, 2000), 29: (Jean et al., 1996), 30: (Kassahun et al., 2005)

DMD #39180

Table 2. List of compounds categorized according to the results of the [³⁵S]GSH trapping assay and the TDI assay

| Group (GSH trapping/TDI) | 1 [#] (-/-) | 2 ^{*#} (-/+) | 3 [*] (+/-) | 4 [*] (+/+) |
|---|------------------------------|---------------------------|--------------------------|---------------------------|
| Compound name | Aminopyrine | Amlodipine | Acetaminophen | Benzbromarone |
| | Caffeine | Donepezil | Amodiaquin | Clopidogrel |
| | Carbamazepine | Erythromycin | Atorvastatin | Clozapine |
| | Celecoxib | Fluoxetine | Diclofenac | Ethinylestradiol |
| | Levofloxacin | Indomethacin | Flutamide | Nevirapine |
| | Olmesartan | Pioglitazone | Furosemide | Olanzapine |
| | Pravastatin | Ritonavir | Imipramine | Propranolol |
| | Tamoxifen | Tacrine | Phenytoin | Rosiglitazone |
| | Valproic acid | Warfarin | Procainamide | Ticlopidine |
| | Valsartan | Zafirlukast | Sulfamethoxazole | Tienilic acid |
| | Zomepirac | | | Verapamil |
| Extent of CB (pmol/mg protein) Mean ± S.D. (Min - Max) | 8.98 ± 8.60 (N.D. - 30.9) | 91.9 ± 120 (7.1 - 253) | 104 ± 115 (3.2 - 352) | 353 ± 323 (44.7 - 938) |

*, significantly different from group 1 (p < 0.05). #, significantly different from group 4 (p < 0.05).

N.D.; not determined

DMD #39180

Table 3. The intrinsic clearance for forming RMs

The intrinsic clearance for forming RMs was calculated from sum of $CL_{int, RMs (GSH)}$ and $CL_{int, RMs (TDI)}$. $CL_{int, RMs (GSH)}$ is the intrinsic clearance for forming RMs based on the formation rate of [³⁵S]GS adducts and $CL_{int, RMs (TDI)}$ is the intrinsic clearance for forming RMs based on the enzyme inactivation rate in TDI assay.

| Compound | $CL_{int, RMs (GSH)}$ ($\mu\text{L}/\text{min}/\text{mg protein}$) | $CL_{int, RMs (TDI)}$ ($\mu\text{L}/\text{min}/\text{mg protein}$) | $CL_{int, RMs}$ ($\mu\text{L}/\text{min}/\text{mg protein}$) |
|------------------|---|---|---|
| Acetaminophen | 0.198 | N.D. | 0.198 |
| Aminopyrine | N.D. | N.D. | N.D. |
| Amlodipine | N.D. | 0.020 | 0.020 |
| Amodiaquin | 0.021 | N.D. | 0.021 |
| Atorvastatin | 0.127 | N.D. | 0.127 |
| Benzbromarone | 0.03 | 0.002 | 0.032 |
| Caffeine | N.D. | N.D. | N.D. |
| Carbamazepine | N.D. | N.D. | N.D. |
| Celecoxib | N.D. | N.D. | N.D. |
| Clopidogrel | 0.236 | 0.848 | 1.084 |
| Clozapine | 0.147 | 0.012 | 0.159 |
| Diclofenac | 0.01 | N.D. | 0.010 |
| Donepezil | N.D. | N.D. | 0.001 |
| Erythromycin | N.D. | 0.021 | 0.021 |
| Ethinylestradiol | 0.34 | 0.087 | 0.427 |
| Fluoxetine | N.D. | 0.008 | 0.008 |
| Flutamide | 0.02 | N.D. | 0.020 |
| Furosemide | 0.072 | N.D. | 0.072 |
| Imipramine | 0.012 | N.D. | 0.012 |
| Indometacin | N.D. | 0.001 | 0.001 |
| Levofloxacin | N.D. | N.D. | N.D. |
| Nevirapine | 0.012 | 0.001 | 0.013 |
| Olanzapine | 0.113 | 0.006 | 0.119 |
| Olmesartan | N.D. | N.D. | N.D. |
| phenytoin | 0.012 | N.D. | 0.012 |
| Pioglitazone | N.D. | 0.036 | 0.036 |
| Pravastatin | N.D. | N.D. | N.D. |
| Procainamide | 0.413 | N.D. | 0.413 |
| Propranolol | 0.027 | 0.004 | 0.031 |
| Ritonavir | N.D. | 3.550 | 3.550 |
| Rosiglitazone | 0.022 | 0.028 | 0.048 |
| Sulfamethoxazole | 0.213 | N.D. | 0.213 |
| Tacrine | N.D. | 0.007 | 0.007 |
| Tamoxifen | N.D. | N.D. | N.D. |
| Ticlopidine | 0.431 | 2.030 | 2.461 |
| Tienilic acid | 0.042 | 0.069 | 0.111 |
| Valproic acid | N.D. | N.D. | N.D. |
| Valsartan | N.D. | N.D. | N.D. |
| Verapamil | 0.048 | 0.026 | 0.074 |
| warfarin | N.D. | 0.003 | 0.003 |
| Zafirlukast | N.D. | 0.207 | 0.207 |
| Zomepirac | N.D. | N.D. | N.D. |

N.D.; not determined

Figure 1




Figure 2




Figure 3

